Key result
Entry inhibitors like DAS-181 show broad-spectrum antiviral potential against sialic-acid-dependent viruses in early evaluations.
Why the study?
The number of treatable viral infections remains limited and resistance to current drug regimens is growing, necessitating additional strategies such as targeting viral attachment and entry.
Entry inhibitors targeting sialic acid interactions offer a promising strategy for developing broad-spectrum antivirals against respiratory and ocular viruses.
May expand antiviral strategies for clinicians; leaves open need for randomized efficacy trials.
Over the past decades, several antiviral drugs have been developed to treat a range of infections. Yet the number of treatable viral infections is still limited, and resistance to current drug regimens is an ever-growing problem. Therefore, additional strategies are needed to provide a rapid cure for infected individuals. An interesting target for antiviral drugs is the process of viral attachment and entry into the cell. Although most viruses use distinct host receptors for attachment to the target cell, some viruses share receptors, of which sialic acids are a common example. This review aims to give an update on entry inhibitors for a range of sialic-acid-targeting viruses and provides insight into the prospects for those with broad-spectrum potential.
No takes yet. Share an insight, caveat, or question.
Heida et al. (2020) conducted a review in Sialic-acid-targeting viral infections. Sialic-acid-targeting entry inhibitors was evaluated. Entry inhibitors targeting sialic acids, such as DAS-181, demonstrate broad-spectrum antiviral potential against multiple sialic-acid-dependent viruses in preclinical and early clinical evaluations.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: